Asset Details
Do you wish to reserve the book?
Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
Do you wish to request the book?
Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant
2007
Overview
Previously, we have shown the potency of recombinant Adenovirus serotype 35 viral vaccines (rAd35) to induce strong immune response against the circumsporozoite protein (CS) of the plasmodium parasite. To further optimize immunogenicity of Ad35-based malaria vaccines we formulated rAd35.CS vaccine with aluminium phosphate adjuvant (AlPO
4). In contrast to the conventional protein based vaccines no absorption to aluminium adjuvant was observed and rAd35 viral
in vitro infectivity in mammalian cells was preserved. Immunization with Ad35.CS formulated with AlPO
4 resulted in significantly higher CS specific T and B cell responses in mice upon either single or prime-boost vaccination regimens as compared to rAd35.CS alone. With these results we report for the first time the feasibility of using an AlPO
4 adjuvant to increase the potency of a live adenovirus serotype 35-based vaccine.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adjuvant
/ Adjuvants, Immunologic - chemistry
/ Adjuvants, Immunologic - pharmacology
/ Aluminum
/ Aluminum Compounds - chemistry
/ Aluminum Compounds - pharmacology
/ Animals
/ Antibody Formation - immunology
/ Antigens
/ DNA
/ Dose-Response Relationship, Drug
/ Female
/ Fluorescent Antibody Technique, Indirect
/ Immunity, Cellular - immunology
/ Malaria
/ Malaria Vaccines - chemistry
/ Malaria Vaccines - immunology
/ Mice
/ Proteins
/ Reverse Transcriptase Polymerase Chain Reaction
/ Rodents
/ Vaccines
/ Vaccines, Synthetic - chemistry
